Avoid common mistakes on your manuscript.
In the section “Material and Methods—Chemicals” it was stated that the drug lumiracoxib was provided by Novartis Pharmaceuticals (São Paulo, SP, Brazil). However, for use in experiments described specifically in this article, this drug was extracted from tablets of Prexige® 400 mg (Novartis) according to methodology previously described in detail by our research group (1).
1. Moreira TS, Cid YP, Pierre MBR, Kummerle AE, Fraga CAM, Sousa VP. Extração e purificação de fármacos antiinflamatórios não esteroidais ciclooxigenase-2 seletivos. Química Nova. 2009;32(5):1324–8.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1208/s12249-010-9420-1.
Rights and permissions
About this article
Cite this article
Moreira, T.S., de Sousa, V.P. & Pierre, M.B.R. Erratum to: A Novel Transdermal Delivery System for the Anti-Inflammatory Lumiracoxib: Influence of Oleic Acid on In Vitro Percutaneous Absorption and In Vivo Potential Cutaneous Irritation. AAPS PharmSciTech 11, 719 (2010). https://doi.org/10.1208/s12249-010-9433-9
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-010-9433-9